CRISPR Therapeutics
CRSP
435 hedge funds and large institutions have $3.28B invested in CRISPR Therapeutics in 2022 Q2 according to their latest regulatory filings, with 59 funds opening new positions, 124 increasing their positions, 122 reducing their positions, and 63 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
5.41% more ownership
Funds ownership: 66.23% → 71.64% (+5.4%)
6% more call options, than puts
Call options by funds: $193M | Put options by funds: $182M
2% more repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 122
6% less first-time investments, than exits
New positions opened: 59 | Existing positions closed: 63
3% less funds holding
Funds holding: 447 → 435 (-12)
5% less capital invested
Capital invested by funds: $3.47B → $3.28B (-$186M)
Top Buyers
Top Sellers
CRSP Hedge Fund Activity: Q2 2022 in Review
435 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2022, worth a combined $3.28B — down 5.4% from $3.47B a quarter earlier.
Sellers outnumbered buyers: 63 funds closed out of CRSP and 59 opened new positions — a net loss of 4 holders — while 122 trimmed existing stakes and 124 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $109M. The largest seller was Allspring Global Investments, cutting an estimated $16.3M.
- 435 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2022, down from 447 in Q1 2022.
- Funds reported $3.28B of CRISPR Therapeutics stock for Q2 2022, down 5.4% quarter-over-quarter.
- 59 funds opened new CRISPR Therapeutics positions in Q2 2022 and 63 closed out, a net change of -4 holders.
- The largest CRISPR Therapeutics buyer in Q2 2022 was T. Rowe Price Associates, an estimated $109M added.
- The largest CRISPR Therapeutics seller in Q2 2022 was Allspring Global Investments, an estimated $16.3M sold.
Based on aggregated 13F filings for Q2 2022.